FIELD: biology.
SUBSTANCE: invention relates to the field of biology and medicine, and is intended for the isolation of tumor cells from peripheral blood. Peripheral blood is diluted with buffer and filtered through a track membrane with pores under reduced pressure, on which antibodies to the surface antigens of secreted tumor cells, epithelial adhesion molecule (EpCAM), are preliminarily immobilized. The track membrane with the tumor cells trapped on it is poured with a solution that preserves the cell structure, which is human or animal blood serum, dried by rotating the track membrane around the axis, and cytological examination of tumor cells is carried out directly on the track membrane.
EFFECT: invention provides an increase in the reliability of determining the pathological nature of tumor cells circulating in the peripheral blood, due to the preservation and improvement of the quality of the cytological picture of the cells retained by the track membrane.
2 cl, 5 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR MULTI ANALYSES OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES BY FILTERING | 2013 |
|
RU2641595C2 |
METHOD FOR DETERMINING CIRCULATING TUMOR CELLS IN PATIENTS WITH BREAST CANCER | 2021 |
|
RU2770284C1 |
METHOD FOR CONDUCTING MULTI-ASSAYS OF RARE CELLS EXTRACTED OR ISOLATED FROM BIOLOGICAL SAMPLES BY FILTRATION | 2013 |
|
RU2765808C2 |
METHOD FOR DETECTING TUMOUR CELLS CIRCULATING IN BLOOD BY MULTIPARAMETER FLOW CYTOMETRY | 2024 |
|
RU2825188C2 |
METHOD FOR DETECTING OR RECOVERING/PRODUCING A CIRCULATING TUMOR CELL USING A CELL PROLIFERATION TECHNIQUE | 2016 |
|
RU2707083C1 |
MOUSE HYBRIDOMA S79 - PRODUCER OF MONOCLONAL ANTIBODY SHOWING SPECIFICITY TO HUMAN NUCLEOLUS PROTEIN SURF-6 | 2010 |
|
RU2422516C1 |
INTRODUCTION OF DENDRITIC CELLS EXPOSED TO PARTIAL AGING IN VITRO, FOR TUMOUR TREATMENT | 2003 |
|
RU2348418C2 |
THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
METHOD OF REVERSIBLE INHIBITION IN TUMOR CELLS OF HEPATOCELLULAR CARCINOMA OF GENE EXPRESSION CODING SYNTHESIS OF APOLIPOPROTEIN B | 2018 |
|
RU2704998C1 |
Authors
Dates
2021-10-19—Published
2021-02-12—Filed